Year: 2025
Type: review
Abstract: Diabetes affects an estimated 828 million people globally, with approximately 44% living in China and India. Rural residents with diabetes in these countries face significant challenges in access to care. Although digital health interventions are increasingly used to reach underserved populations, considerable knowledge gaps exist. This mini-review presents the first comparative analysis of digital health implementations for diabetes care in rural China and India, comprising clinical decision support tools, telemedicine, and mobile health applications. The review examines how their distinct health system structures influence technology adoption and clinical outcomes. China's hierarchical administrative structure facilitates standardized nationwide platforms with consistent protocols, while India's federal system enables diverse localized innovations that accommodate regional diversity. Cluster-randomized trials for digital health tools in rural China show significant improvements in glycemic control. In India, interventions examined in this review were associated with improved health behaviors and medication adherence. Both countries demonstrate that digital interventions leveraging existing social structures and co-created with stakeholders yield better outcomes than standard care approaches. This analysis provides actionable insights for policymakers globally while identifying valuable opportunities for knowledge exchange between these two nations that together are home to nearly half of all people living with diabetes worldwide.
Source: World Journal of Diabetes
Institutions: Ben-Gurion University of the Negev, University of Geneva, University Hospital of Geneva, National Center for Chronic and Noncommunicable Disease Control and Prevention, World Health Organization, Nanchang University, All India Institute of Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College
Language: English
Subfield: General Health Professions
Field: Health Professions
Domain: Health Sciences
Open Access status: diamond
Funders: Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, World Health Organization, UK Research and Innovation, Society for Endocrinology, Imperial College London, Society for Endocrinology, Metabolism and Diabetes of South Africa, Novo Nordisk, National Institutes of Health, Centers for Disease Control and Prevention, Medical Research Council, Research England, Fogarty International Center
OpenAlex ID: W4414167366
